{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:39:55Z","timestamp":1759228795128},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1016\/j.clinthera.2006.02.003","type":"journal-article","created":{"date-parts":[[2006,5,9]],"date-time":"2006-05-09T11:13:20Z","timestamp":1147173200000},"page":"243-250","source":"Crossref","is-referenced-by-count":6,"title":["The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: A retrospective chart review involving up to 8 years of follow-up"],"prefix":"10.1016","volume":"28","author":[{"given":"Gregory A.","family":"Nichols","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol E.","family":"Koro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiley","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"Bowlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis L.","family":"Sprecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.02.003_bib1","doi-asserted-by":"crossref","first-page":"9B","DOI":"10.1016\/0002-9149(83)90649-5","article-title":"High-density lipoproteins: Epidemiologic profile and risks of coronary artery disease","volume":"52","author":"Kannel","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2006.02.003_bib2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med."},{"key":"10.1016\/j.clinthera.2006.02.003_bib3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/oxfordjournals.aje.a112683","article-title":"High density lipoprotein cholesterol and incidence of coronary heart disease\u2013the Israeli Ischemic Heart Disease Study","volume":"109","author":"Goldbourt","year":"1979","journal-title":"Am J Epidemiol."},{"key":"10.1016\/j.clinthera.2006.02.003_bib4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/0002-9149(92)90550-I","article-title":"Relation of high-density lipoprotein cholesterol and triglycerides to incidence of athero-sclerotic coronary artery disease (the PROCAM experience) Prospective Cardiovascular Munster study","volume":"70","author":"Assmann","year":"1992","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.clinthera.2006.02.003_bib5","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/01.CIR.97.11.1029","article-title":"Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study","volume":"97","author":"Jeppesen","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2006.02.003_bib6","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0002-9149(99)80761-9","article-title":"Distribution of lipids in 8,500 men with coronary artery disease","volume":"75","author":"Rubins","year":"1995","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.clinthera.2006.02.003_bib7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jama.260.5.641","article-title":"Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study","volume":"260","author":"Manninen","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.02.003_bib8","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.02.003_bib9","doi-asserted-by":"crossref","first-page":"10H","DOI":"10.1016\/0002-9149(92)91084-H","article-title":"Role of triglycerides in coronary artery disease: Lessons from the Prospective Cardiovascular Munster Study","volume":"70","author":"Assmann","year":"1992","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.clinthera.2006.02.003_bib10","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.02.003_bib11","author":"Stokes","year":"2000"},{"key":"10.1016\/j.clinthera.2006.02.003_bib12","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study","volume":"357","year":"2001","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2006.02.003_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2006.02.003_bib14","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/jama.256.20.2835","article-title":"Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study","volume":"256","author":"Castelli","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.02.003_bib15","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1001\/jama.293.15.1868","article-title":"Secular trends in cardiovascular disease risk factors according to body mass index in US adults","volume":"293","author":"Gregg","year":"2005","journal-title":"JAMA."},{"key":"10.1016\/j.clinthera.2006.02.003_bib16","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2165\/00003495-200464190-00003","article-title":"Role of fibric acid derivatives in the management of risk factors for coronary heart disease","volume":"64","author":"Despres","year":"2004","journal-title":"Drugs"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806000439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806000439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T18:36:58Z","timestamp":1555612618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806000439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S0149291806000439"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.02.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}